Evidence map›Paper›PMID 41122172›Full record

ArticleFrontiers in immunology2025

A high eosinophil proportion increases the risk of skin-related adverse events induced by apalutamide in patients with prostate cancer.

Yoshihiko Tasaki, Taku Naiki, Yoshihisa Mimura, Yosuke Sugiyama, Misato Tomita, Toshiharu Morikawa, Takashi Nagai, Rei Unno, Toshiki Etani, Shuzo Hamamoto and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yoshihiko TasakiDepartment of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Taku NaikiDepartment of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Yoshihisa MimuraDepartment of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Yosuke SugiyamaDepartment of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Misato TomitaDepartment of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Toshiharu MorikawaDepartment of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Takashi NagaiDepartment of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Rei UnnoDepartment of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Toshiki EtaniDepartment of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Shuzo HamamotoDepartment of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Yukihiro UmemotoDepartment of Urology, Nagoya City University West Medical Center, Nagoya, Aichi, Japan.
Takahiro YasuiDepartment of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Yoko Furukawa-HibiDepartment of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Skin-related adverse events (AEs) induced by apalutamide occur frequently in Japanese patients with prostate cancer. However, biomarkers for predicting these skin-related AEs have not yet been identified. Therefore, this study investigated whether the proportion of eosinophils could serve as a predictive biomarker for skin-related AEs in Japanese patients with prostate cancer treated with apalutamide. Methods: A total of 109 patients were enrolled in this study. Among them, 79 patients with prostate cancer who received apalutamide were categorized into two groups: the skin AE group (n = 45) and the non-skin AE group (n = 34), based on whether they experienced skin-related AEs of any grade. The eosinophil proportions in baseline samples collected before treatment were then analyzed. Results: The baseline eosinophil proportion was significantly higher in the skin AE group compared with the non-skin AE group ( Conclusion: The baseline eosinophil proportion may serve as a predictive biomarker for skin-related AEs of any grade in Japanese patients with prostate cancer treated with apalutamide.

Indexed as

Antineoplastic AgentsDrug EruptionsEosinophilsProstatic NeoplasmsThiohydantoinsAgedAged, 80 and overHumansLeukocyte CountMaleMiddle AgedSkinAntineoplastic AgentsapalutamideThiohydantoinsapalutamideeosinophilprostate cancerpruritusrash

Identifiers

PMID41122172
PMCPMC12536007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.